New drug BL-M17D1 tested in patients with Hard-to-Treat cancers
NCT ID NCT06503783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumors. Participants receive the drug by IV every 3 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M17D1 (a drug given by IV infusion every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for advanced breast cancer and other solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase I trial with only 20 participants, so it is primarily testing safety and dosing. The drug may not prove effective, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact